Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rimsza

Showing results (81-90 of 203) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
British Journal of Haematology|October 16, 2024
CDK8/19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytesZhi-Jian Liu, Christopher Thom, Ioana I Nitulescu, et al.
Blood|December 15, 2011
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphomaSarah T Wilkinson, Kristie A Vanpatten, Diane R Fernandez, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Chemical Communications (Cambridge, England)|December 23, 2025
Tuning CO<sub>2</sub> uptake capacity in covalent organic frameworks <i>via</i> metal dopingHarrison D Root, Matthew J Hurlock, Jessica M Rimsza, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2007
Umbilical cord blood produces small megakaryocytes after transplantationMark Ignatz, Martha Sola-Visner, Lisa M Rimsza, et al.
Cancer Biology & Therapy|August 29, 2013
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitorsAna A Tula-Sanchez, Aaron P Havas, Peter J Alonge, et al.
British Journal of Haematology|July 17, 2021
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic featuresJennifer R Chapman, Alyssa C Bouska, Weiwei Zhang, et al.
NAR Cancer|October 23, 2020
Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphomaYing-Zhi Xu, Piroon Jenjaroenpun, Thidathip Wongsurawat, et al.
Pageof 21

Showing results (81-90 of 203) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
British Journal of Haematology|October 16, 2024
CDK8/19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytesZhi-Jian Liu, Christopher Thom, Ioana I Nitulescu, et al.
Blood|December 15, 2011
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphomaSarah T Wilkinson, Kristie A Vanpatten, Diane R Fernandez, et al.
Haematologica|January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneDaniel O Persky, David Dornan, Bryan H Goldman, et al.
Chemical Communications (Cambridge, England)|December 23, 2025
Tuning CO<sub>2</sub> uptake capacity in covalent organic frameworks <i>via</i> metal dopingHarrison D Root, Matthew J Hurlock, Jessica M Rimsza, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2007
Umbilical cord blood produces small megakaryocytes after transplantationMark Ignatz, Martha Sola-Visner, Lisa M Rimsza, et al.
Cancer Biology & Therapy|August 29, 2013
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitorsAna A Tula-Sanchez, Aaron P Havas, Peter J Alonge, et al.
British Journal of Haematology|July 17, 2021
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic featuresJennifer R Chapman, Alyssa C Bouska, Weiwei Zhang, et al.
NAR Cancer|October 23, 2020
Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphomaYing-Zhi Xu, Piroon Jenjaroenpun, Thidathip Wongsurawat, et al.
Pageof 21